Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04449263 · ClinicalTrials.gov registry record · NA

Comparing the Performance of 1 Day Multifocal Contact Lenses

A NA study of Presbyopia, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
60
Enrollment target
5
Study locations

NCT04449263 is a NA study of Presbyopia that has completed, run by CooperVision. The registered enrollment target is 60 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (78% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04449263, a NA study of Presbyopia, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

The objective of the study was to compare the lens handling and performance of Lens A to habitually worn multifocal contact lenses and to the competitor Lens B.

Conditions Studied

Interventions

  • DEVICE Lens A
  • DEVICE Lens B
  • DEVICE Habitual Lenses

Study Locations (5)

California

  • Scripps Poway Eyecare - San Diego
  • Golden Optometric Group - Whittier

Florida

  • Golden Vision - Sarasota

Kansas

  • Kannarr Eye Care - Pittsburg

Ohio

  • ProCare Vision Center - Granville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2020-07-27
Est. Completion 2020-12-30
Phase NA

Sponsor

CooperVision

64 total trials

What the Registry Record Tells You About NCT04449263

The ClinicalTrials.gov registry entry for NCT04449263 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (78% lower). The listed sponsor is CooperVision, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Lens A is the first listed.

NCT04449263 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT04449263 about?

NCT04449263 is a clinical study titled "Comparing the Performance of 1 Day Multifocal Contact Lenses". The objective of the study was to compare the lens handling and performance of Lens A to habitually worn multifocal contact lenses and to the competitor Lens B.

What is the current status of trial NCT04449263?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2020-07-27. Estimated completion is 2020-12-30.

What conditions does trial NCT04449263 study?

This clinical trial studies the following conditions: Presbyopia.

What interventions are being tested in trial NCT04449263?

The interventions under investigation include: Lens A (DEVICE), Lens B (DEVICE), Habitual Lenses (DEVICE).

Who is sponsoring clinical trial NCT04449263?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04449263 being conducted?

This trial has 5 study locations across California, Florida, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Presbyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.